Detailed financial statements for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $10.84, DMAA trades at a P/E of 55.22 and an ROE of 2.92%. Market capitalisation stands at $263M.
Balance sheet quality for DMAA: current ratio of 0.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is below average: free cash flow of -$539187 represents -9% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Income Statement (10y)
| Year | 2024 | 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Research & Development | 0 | 0 |
| Selling, General & Admin | $480 | $2.8M |
| Operating Expenses | $480 | $2.8M |
| Operating Income | -$479 | -$2.8M |
| EBITDA | -$279845 | -$2.8M |
| Interest Expense | 0 | 0 |
| Pre-tax Income | -$479 | $5.9M |
| Income Tax | 0 | 0 |
| Net Income | -$479 | $5.9M |
| EPS | $-0.06 | $0.19 |
| EPS (Diluted) | $-0.06 | $0.19 |
| Shares Outstanding (Diluted) | $8.6M | $21.0M |
Balance Sheet (10y)
| Year | 2024 | 2025 |
|---|---|---|
| Cash & Equivalents | $1351 | $6137 |
| Short-term Investments | 0 | 0 |
| Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Total Current Assets | $4991 | $12191 |
| Property, Plant & Equipment | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Total Assets | $551 | $239.9M |
| Accounts Payable | 0 | $222184 |
| Short-term Debt | $662 | 0 |
| Total Current Liabilities | $796 | $376172 |
| Long-term Debt | 0 | 0 |
| Total Liabilities | $796 | $7.3M |
| Retained Earnings | -$279 | -$7.3M |
| Total Equity | -$244 | $232.6M |
| Total Debt | $662 | 0 |
| Net Debt | -$689 | -$6137 |
| Working Capital | $4195 | -$363981 |
Cash Flow (10y)
| Year | 2024 | 2025 |
|---|---|---|
| Net Income | -$479 | $4.0M |
| Depreciation & Amortization | 0 | 0 |
| Stock-based Compensation | 0 | 0 |
| Change in Working Capital | $132 | $138850 |
| Operating Cash Flow | -$295 | -$539187 |
| Capital Expenditure | $5 | 0 |
| Acquisitions | 0 | 0 |
| Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Free Cash Flow | -$295 | -$539187 |
Growth & Margins (10y)
| Year | 2024 | 2025 |
|---|---|---|
| Net Income Growth (YoY) | +1240317.7% | |
| EPS Growth (YoY) | +439.3% | |
| Shares Change (YoY) | +145.1% | |
| FCF Growth (YoY) | -182675.3% | |
| Effective Tax Rate | -0.0% | 0.0% |
Per-Share Data (10y)
| Year | 2024 | 2025 |
|---|---|---|
| FCF Per Share | $-0.00 | $-0.03 |
| Dividends Per Share | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $8.6M | $21.0M |
What to look at in Financial Services
Asset managers, brokers, fintech, exchanges. They are not banks — look at AUM, fees and FCF quality.
- 5y revenue growth — Without growth, there is no long-term value creation
- Operating margin — Good asset managers have >30% margins thanks to scalability
- ROE — Quality financial services have a consistent ROE >15%
- FCF / Net Income — Earnings quality — >90% expected in capital-light businesses
- Debt / Equity — Fintech and brokers with high D/E are time bombs in crises
- P/E vs own 5y — Asset managers have stable multiples in well-known ranges
- Dividend yield + buybacks — These businesses return a lot of capital — look at total yield (div + buybacks)
Profitability
| Return on Equity | 2.92% |
| Return on Invested Capital | -1.82% |
| Return on Assets | 4.15% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 0.02 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 17.88 |
Key Ratios (10y)
| Year | 2024 | 2025 |
|---|---|---|
| P/E | -177.86 | 54.58 |
| P/B | -349865.41 | 0.94 |
| P/S | 0.00 | 0.00 |
| Gross Margin | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% |
Related companies: ALF · LOKV · MLAC · OYSE · RTAC · SIMA · TACH
Explore sector: Financial Services · Shell Companies
More sections of DMAA: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks